RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index

J Clin Psychopharmacol 37(4):401-404 · 2017 · PMID 28590369

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

1,142편 검색→1,077편 판독→302편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Donepezil adverse events in Alzheimer disease (donepezil[tiab] OR Aricept[tiab]) AND (adverse[tiab] OR side effect*[tiab] OR toxicity[tiab] OR safety[tiab]) AND (Alzheimer*[tiab] OR dementia[tiab])

출판 연도

1994: 1편119941996: 1편11997: 1편11998: 5편51999: 3편32000: 7편720002001: 7편72002: 11편112003: 11편112004: 14편142005: 8편820052006: 9편92007: 7편72008: 7편72009: 13편132010: 10편1020102011: 7편72012: 19편192013: 6편62014: 10편102015: 11편1120152016: 12편122017: 13편132018: 8편82019: 15편152020: 10편1020202021: 16편162022: 13편132023: 9편92024: 10편102025: 9편92026: 19편192026

선별된 302편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01double-blind · trial93편

  1. 0.96

    Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

    Hong YJ, Han HJ, Youn YC et al. · Alzheimer's research & therapy · 2019

  2. 0.96

    Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease

    Tariot P, Salloway S, Yardley J et al. · BMC research notes · 2012

  3. 0.95

    Donepezil: tolerability and safety in Alzheimer's disease

    Pratt RD, Perdomo CA, Surick IW et al. · International journal of clinical practice · 2002

  4. 0.95

    Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease

    Jia J, Wei C, Chen W et al. · Journal of Alzheimer's disease : JAD · 2020

  5. 0.95

    Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

    Farlow M, Veloso F, Moline M et al. · BMC neurology · 2011

  6. 0.95

    Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial

    Hong YJ, Han HJ, Youn YC et al. · Dementia and geriatric cognitive disorders · 2021

  7. 0.94

    Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease

    Burns A, Gauthier S, Perdomo C · International journal of geriatric psychiatry · 2007

  8. 0.94

    A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

    Rogers SL, Farlow MR, Doody RS et al. · Neurology · 1998

  9. 0.94

    A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease

    Relkin NR, Reichman WE, Orazem J et al. · Dementia and geriatric cognitive disorders · 2003

  10. 0.94

    Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine

    Doody RS, Geldmacher DS, Farlow MR et al. · Dementia and geriatric cognitive disorders · 2012

  11. 0.94

    A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease

    Wilkinson DG, Passmore AP, Bullock R et al. · International journal of clinical practice · 2002

  12. 0.94

    Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

    Doody RS, Geldmacher DS, Gordon B et al. · Archives of neurology · 2001

  13. 0.93

    Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group

    Homma A, Takeda M, Imai Y et al. · Dementia and geriatric cognitive disorders · 2000

  14. 0.93

    Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease

    Griffith P, Lichtenberg P, Goldman R et al. · Journal of the National Medical Association · 2006

  15. 0.93

    Donepezil therapy in clinical practice: a randomized crossover study

    Greenberg SM, Tennis MK, Brown LB et al. · Archives of neurology · 2000

  16. 0.93

    Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

    Farlow MR, Salloway S, Tariot PN et al. · Clinical therapeutics · 2010

  17. 0.93

    Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease

    Doody RS, Corey-Bloom J, Zhang R et al. · Drugs & aging · 2008

  18. 0.92

    Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

    Rogers SL, Doody RS, Pratt RD et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2000

  19. 0.92

    A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

    Winblad B, Engedal K, Soininen H et al. · Neurology · 2001

  20. 0.92

    Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

    Rogers SL, Doody RS, Mohs RC et al. · Archives of internal medicine · 1998

  21. 0.92

    A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

    Feldman H, Gauthier S, Hecker J et al. · Neurology · 2001

  22. 0.92

    Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease

    Han SH, Lee JH, Kim SY et al. · Acta neurologica Scandinavica · 2017

  23. 0.92

    A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

    Tariot PN, Cummings JL, Katz IR et al. · Journal of the American Geriatrics Society · 2001

  24. 0.92

    Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study

    Boada-Rovira M, Brodaty H, Cras P et al. · Drugs & aging · 2004

  25. 0.92

    The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group

    Rogers SL, Friedhoff LT · Dementia (Basel, Switzerland) · 1996

  26. 0.91

    Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

    Rogers SL, Friedhoff LT · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 1998

  27. 0.91

    Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial

    Jia J, Wei C, Jia L et al. · Journal of Alzheimer's disease : JAD · 2017

  28. 0.91

    Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial

    Homma A, Atarashi H, Kubota N et al. · Journal of Alzheimer's disease : JAD · 2016

  29. 0.90

    Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease

    Salloway S, Mintzer J, Cummings JL et al. · American journal of Alzheimer's disease and other dementias · 2012

  30. 0.90

    A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

    Ridha BH, Crutch S, Cutler D et al. · Alzheimer's research & therapy · 2018

  31. 0.90

    Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease

    Chase TN, Farlow MR, Clarence-Smith K · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017

  32. 0.90

    Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan

    Homma A, Imai Y, Tago H et al. · Dementia and geriatric cognitive disorders · 2009

  33. 0.90

    Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

    Winblad B, Kilander L, Eriksson S et al. · Lancet (London, England) · 2006

  34. 0.90

    Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

    Bullock R, Touchon J, Bergman H et al. · Current medical research and opinion · 2005

  35. 0.90

    3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

    Winblad B, Wimo A, Engedal K et al. · Dementia and geriatric cognitive disorders · 2006

  36. 0.89

    Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study

    Nakamura Y, Kim R, Nishiyama K et al. · Geriatrics & gerontology international · 2023

  37. 0.88

    A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

    Jones RW, Soininen H, Hager K et al. · International journal of geriatric psychiatry · 2004

  38. 0.88

    Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

    Gauthier S, Feldman H, Hecker J et al. · Current medical research and opinion · 2002

  39. 0.87

    A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study

    Prasher VP, Huxley A, Haque MS · International journal of geriatric psychiatry · 2002

  40. 0.87

    A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease

    Han HJ, Park MY, Park KW et al. · Journal of clinical neurology (Seoul, Korea) · 2022

  41. 0.86

    A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease

    Akhondzadeh S, Shafiee Sabet M, Harirchian MH et al. · Psychopharmacology · 2010

  42. 0.86

    Donepezil preserves cognition and global function in patients with severe Alzheimer disease

    Black SE, Doody R, Li H et al. · Neurology · 2007

  43. 0.86

    Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany

    Froelich L, Gertz HJ, Heun R et al. · Dementia and geriatric cognitive disorders · 2004

  44. 0.85

    Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety

    Rocca P, Cocuzza E, Marchiaro L et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2002

  45. 0.83

    Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study

    Santens P, Ventura M · Acta neurologica Belgica · 2003

  46. 0.83

    The effects of donepezil in Alzheimer's disease - results from a multinational trial

    Burns A, Rossor M, Hecker J et al. · Dementia and geriatric cognitive disorders · 1999

  47. 0.82

    Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study

    Zhang Z, Yu L, Gaudig M et al. · Neuropsychiatric disease and treatment · 2012

  48. 0.82

    Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study

    Sadowsky CH, Farlow MR, Atkinson L et al. · Primary care companion to the Journal of clinical psychiatry · 2005

  49. 0.81

    Management of cognition and function: new results from the clinical trials programme of Aricept(R) (donepezil HCl)

    Knopman DS · The international journal of neuropsychopharmacology · 2000

  50. 0.81

    Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

    Winblad B, Black SE, Homma A et al. · Current medical research and opinion · 2009

  51. 0.78

    Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study

    Doody RS, Ferris S, Salloway S et al. · American journal of Alzheimer's disease and other dementias · 2010

  52. 0.78

    Acupuncture as an adjunct therapy for mild Alzheimer's disease: A randomized clinical trial

    Kong X, Han R, Fan X et al. · Journal of Alzheimer's disease : JAD · 2026

  53. 0.77

    Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study

    Ancoli-Israel S, Amatniek J, Ascher S et al. · Alzheimer disease and associated disorders · 2005

  54. 0.76

    Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

    Courtney C, Farrell D, Gray R et al. · Lancet (London, England) · 2004

  55. 0.74

    Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil

    Alvarez XA, Cacabelos R, Sampedro C et al. · Current Alzheimer research · 2011

  56. 0.74

    A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil

    Finkel SI, Mintzer JE, Dysken M et al. · International journal of geriatric psychiatry · 2004

  57. 0.74

    Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial

    Jia Y, Zhang X, Yu J et al. · BMC complementary and alternative medicine · 2017

  58. 0.74

    Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

    Atri A, Molinuevo JL, Lemming O et al. · Alzheimer's research & therapy · 2013

  59. 0.74

    Donepezil

    Bryson HM, Benfield P · Drugs & aging · 1997

  60. 0.73

    Donepezil 23 mg: An empty suit

    Knopman DS · Neurology. Clinical practice · 2012

  61. 0.73

    Effectiveness of Anti-Dementia Drugs in Extremely Severe Alzheimer's Disease: A 12-Week, Multicenter, Randomized, Single-Blind Study

    Hong YJ, Choi SH, Jeong JH et al. · Journal of Alzheimer's disease : JAD · 2018

  62. 0.72

    Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial

    Tian J, Shi J, Li T et al. · Evidence-based complementary and alternative medicine : eCAM · 2017

  63. 0.70

    Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial

    Doody RS, Ferris SH, Salloway S et al. · Neurology · 2009

  64. 0.69

    Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

    Whitehead A, Perdomo C, Pratt RD et al. · International journal of geriatric psychiatry · 2004

  65. 0.69

    Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study

    Gauthier S, Rountree S, Finn B et al. · Journal of Alzheimer's disease : JAD · 2015

  66. 0.68

    Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial

    Pakdaman H, Harandi AA, Hatamian H et al. · Dementia and geriatric cognitive disorders extra · 2015

  67. 0.68

    Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease

    Chen Z, Zhang H, Guo Y et al. · NPJ digital medicine · 2021

  68. 0.68

    Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size

    Roman GC, Salloway S, Black SE et al. · Stroke · 2010

  69. 0.67

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA)

    Shim Y, Han HJ, Park KW et al. · Journal of Alzheimer's disease : JAD · 2022

  70. 0.66

    Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

    Seltzer B, Zolnouni P, Nunez M et al. · Archives of neurology · 2004

  71. 0.66

    Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

    Tariot PN, Farlow MR, Grossberg GT et al. · JAMA · 2004

  72. 0.66

    ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

    Gault LM, Lenz RA, Ritchie CW et al. · Alzheimer's research & therapy · 2016

  73. 0.65

    Perspectives in the management of Alzheimer's disease: clinical profile of donepezil

    Rogers SL · Dementia and geriatric cognitive disorders · 1998

  74. 0.65

    Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results

    Sadowsky CH, Dengiz A, Meng X et al. · Primary care companion to the Journal of clinical psychiatry · 2010

  75. 0.64

    Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

    Feldman H, Gauthier S, Hecker J et al. · International journal of geriatric psychiatry · 2005

  76. 0.63

    A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia

    Kwon JC, Kim EG, Kim JW et al. · American journal of Alzheimer's disease and other dementias · 2009

  77. 0.62

    Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial

    Devanand DP, Pelton GH, D'Antonio K et al. · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2018

  78. 0.60

    Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

    Salloway S, Ferris S, Kluger A et al. · Neurology · 2004

  79. 0.58

    Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease

    Maher-Edwards G, Watson C, Ascher J et al. · Alzheimer's & dementia (New York, N. Y.) · 2015

  80. 0.58

    Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy

    Reynolds CF3, Butters MA, Lopez O et al. · Archives of general psychiatry · 2011

  81. 0.56

    A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

    Fullerton T, Binneman B, David W et al. · Alzheimer's research & therapy · 2018

  82. 0.56

    Donepezil in vascular dementia: a randomized, placebo-controlled study

    Wilkinson D, Doody R, Helme R et al. · Neurology · 2003

  83. 0.56

    Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease

    Frolich L, Atri A, Ballard C et al. · Journal of Alzheimer's disease : JAD · 2019

  84. 0.56

    Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

    Black S, Roman GC, Geldmacher DS et al. · Stroke · 2003

  85. 0.55

    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Teprenone in Patients with Alzheimer's Disease

    Yokoyama S, Yoshinaga T, Matsuzaki J et al. · Journal of Alzheimer's disease : JAD · 2019

  86. 0.55

    Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease

    Marek GJ, Katz DA, Meier A et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014

  87. 0.54

    Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial

    Shi J, Wei M, Ni J et al. · Journal of translational medicine · 2020

  88. 0.52

    Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study

    Figiel GS, Sadowsky CH, Strigas J et al. · Primary care companion to the Journal of clinical psychiatry · 2008

  89. 0.52

    Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET)

    Lang FM, Mo Y, Sabbagh M et al. · Alzheimer's & dementia (New York, N. Y.) · 2021

  90. 0.52

    A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia

    Haig GM, Pritchett Y, Meier A et al. · Journal of Alzheimer's disease : JAD · 2014

  91. 0.52

    Efficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b Study

    Prabhakar S, Vishnu VY, Modi M et al. · Annals of Indian Academy of Neurology · 2020

  92. 0.51

    Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials

    Passmore AP, Bayer AJ, Steinhagen-Thiessen E · Journal of the neurological sciences · 2005

  93. 0.50

    Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study

    Nirogi R, Ieni J, Goyal VK et al. · Alzheimer's & dementia (New York, N. Y.) · 2022

02state examination · mini-mental79편

  1. 0.94

    Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease

    Carrasco MM, Aguera L, Gil P et al. · Alzheimer disease and associated disorders · 2011

  2. 0.92

    An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease

    Hager K, Calabrese P, Frolich L et al. · Dementia and geriatric cognitive disorders · 2003

  3. 0.91

    Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities

    Rosenblatt A, Gao J, Mackell J et al. · American journal of Alzheimer's disease and other dementias · 2010

  4. 0.91

    Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study

    Mehta S, Chandersekhar K, Prasadrao G et al. · Indian journal of psychiatry · 2012

  5. 0.91

    Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study

    Lopez OL, Mackell JA, Sun Y et al. · Journal of the National Medical Association · 2008

  6. 0.91

    Combined Effects of Donepezil and Memantine on Behavioral and Psychological Symptoms, Cognitive Function, and Daily Living Abilities in Patients With Alzheimer's Disease

    Tu H, Zhou S, Lin J · British journal of hospital medicine (London, England : 2005) · 2025

  7. 0.91

    The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's disease

    Kim TE, Bae JW, Hong S et al. · The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025

  8. 0.91

    Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan

    Nozawa M, Ichimiya Y, Nozawa E et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2009

  9. 0.90

    Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease

    Frolich L, Klinger T, Berger FM · Journal of the neurological sciences · 2002

  10. 0.90

    Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study

    Klinger T, Ibach B, Schoenknecht P et al. · Current medical research and opinion · 2005

  11. 0.89

    Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study

    Yatabe Y, Hashimoto M, Kaneda K et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2013

  12. 0.89

    Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study

    Mossello E, Tonon E, Caleri V et al. · Archives of gerontology and geriatrics. Supplement · 2004

  13. 0.89

    Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia

    Park KH, Yang Y, Chen C et al. · Journal of clinical neurology (Seoul, Korea) · 2021

  14. 0.89

    Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic

    Matthews HP, Korbey J, Wilkinson DG et al. · International journal of geriatric psychiatry · 2000

  15. 0.87

    Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease

    Paleacu D, Mazeh D, Mirecki I et al. · Clinical neuropharmacology · 2002

  16. 0.87

    Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy

    Sakka P, Tsolaki M, Hort J et al. · Current medical research and opinion · 2007

  17. 0.86

    Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD)

    Arai H, Hashimoto N, Sumitomo K et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2018

  18. 0.86

    Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease

    Kim JM, Shin IS, Yoon JS · International psychogeriatrics · 2002

  19. 0.86

    Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study

    Li Dq, Zhou Yp, Yang H · International journal of medical sciences · 2012

  20. 0.86

    Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study

    Rapp M, Burkart M, Kohlmann T et al. · International journal of clinical pharmacology and therapeutics · 2018

  21. 0.85

    Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease

    Sakakibara R, Uchiyama T, Yoshiyama M et al. · Neurourology and urodynamics · 2005

  22. 0.84

    Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trial

    Fischer MHF, Zibrandtsen IC, Johannsen P et al. · Journal of Alzheimer's disease reports · 2024

  23. 0.83

    Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial

    Yancheva S, Ihl R, Nikolova G et al. · Aging & mental health · 2009

  24. 0.83

    Efficacy of donepezil versus donepezil and trazodone in combination cognitive dysfunction in patients with dementia: a randomized controlled trial

    Kheirkhah F, Hamzehkolaee ME, Parvizi S et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2026

  25. 0.82

    Comparative Effectiveness of Rivastigmine and Donepezil in Patients With Alzheimer's Disease: A Retrospective Cohort Study

    Abbas Raja A, Amjad A, Choudhary A et al. · Cureus · 2025

  26. 0.82

    Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option

    Yang H, Han W, Li H · Pakistan journal of pharmaceutical sciences · 2020

  27. 0.82

    Comparative assessment of donepezil memantine and sodium oligomannate on cognitive decline and neuroinflammation in early Alzheimer's disease

    Deng X, Zeng Y, Ding D · Pakistan journal of pharmaceutical sciences · 2026

  28. 0.82

    Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan

    Arai H, Sumitomo K, Sakata Y et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2016

  29. 0.81

    Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease

    Ma SL, Tang NLS, Wat KHY et al. · American journal of Alzheimer's disease and other dementias · 2019

  30. 0.81

    Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

    Touchon J, Bergman H, Bullock R et al. · Current medical research and opinion · 2006

  31. 0.79

    Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study

    Wang J, Guo X, Lu W et al. · Journal of Alzheimer's disease : JAD · 2021

  32. 0.79

    Efficacy and safety of NAD+ ADP-ribosyltransferase 1 agonist versus Donepezil in elderly Chinese patients with Alzheimer disease: A novel target for effective therapy

    Wang J, Yang S, Hu Z et al. · Pakistan journal of pharmaceutical sciences · 2019

  33. 0.79

    Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

    Bullock R, Bergman H, Touchon J et al. · Current medical research and opinion · 2006

  34. 0.78

    Effect of Psychoeducational Intervention on Donepezil Retention Rate and Analysis of Reasons for the Discontinuation in Patients with Alzheimer's Dementia: A Randomized Study

    Kamei T, Kobayashi H, Nishida M et al. · Patient preference and adherence · 2021

  35. 0.78

    A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

    Wilcock G, Howe I, Coles H et al. · Drugs & aging · 2003

  36. 0.78

    Effects of donepezil on cognitive functions and the expression level of beta-amyloid in peripheral blood of patients with Alzheimer's disease

    Ma Y, Ji J, Li G et al. · Experimental and therapeutic medicine · 2018

  37. 0.76

    Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease

    Blesa R, Bullock R, He Y et al. · Pharmacogenetics and genomics · 2006

  38. 0.76

    Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial

    Cumbo E, Ligori LD · Journal of Alzheimer's disease : JAD · 2014

  39. 0.76

    Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil

    Zhao Q, Xie C, Pesco-Koplowitz L et al. · Journal of clinical pharmacology · 2003

  40. 0.76

    Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer's Disease: A Randomized Controlled Trial

    Li YQ, Chen DX, Zhu XT et al. · Chinese journal of integrative medicine · 2026

  41. 0.76

    Efficacy evaluation and metabolomics analysis of Huanglian Jiedu decoction in combination with donepezil for Alzheimer's disease treatment

    Xu M, Yue Y, Huang J · Journal of pharmaceutical and biomedical analysis · 2023

  42. 0.75

    Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial

    Miao Yc, Tian Jz, Shi J et al. · Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine · 2012

  43. 0.75

    Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease

    Fang X, Zhang J, Zhao J et al. · Journal of healthcare engineering · 2022

  44. 0.75

    Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer's disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors

    Yang X, Chen Q · Experimental and therapeutic medicine · 2021

  45. 0.74

    Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study

    Bago Rozankovic P, Rozankovic M, Badzak J et al. · Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology · 2021

  46. 0.73

    Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study

    Gareri P, Putignano D, Castagna A et al. · Journal of Alzheimer's disease : JAD · 2014

  47. 0.73

    Efficacy of Donepezil Hydrochloride plus Olanzapine for Senile Dementia and Its Effect on the Recovery of Cognitive Function

    Zheng W, Sun X, Liu J · Evidence-based complementary and alternative medicine : eCAM · 2022

  48. 0.71

    Efficacy of a high dosage of donepezil for Alzheimer's disease as examined by single-photon emission computed tomography imaging

    Kanaya K, Abe S, Sakai M et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2012

  49. 0.71

    Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial

    Yang Y, Liu JP, Fang JY et al. · Chinese journal of integrative medicine · 2019

  50. 0.70

    Clinical observation on treatment of Alzheimer's disease with Sun's scalp-abdominal acupuncture combined with donepezil hydrochloride

    Zhang SQ, Ma S, Yang TS et al. · Zhen ci yan jiu = Acupuncture research · 2024

  51. 0.69

    Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine

    Wang HC, Liu NY, Zhang S et al. · Chinese journal of integrative medicine · 2020

  52. 0.69

    Efficacy and safety of Woohwangchungsimwon in combination with donepezil for behavioral and psychological symptoms of dementia in probable Alzheimer's disease: An assessor-blinded randomized controlled trial

    Kim MG, Woo SH, Kim GW et al. · Journal of Alzheimer's disease : JAD · 2026

  53. 0.69

    Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease

    Shao ZQ · International journal of clinical and experimental medicine · 2015

  54. 0.69

    Plasma lipid levels in Alzheimer's disease patients treated by Donepezil hydrochloride: a cross-sectional study

    Adunsky A, Chesnin V, Ravona R et al. · Archives of gerontology and geriatrics · 2004

  55. 0.68

    Donepezil in Alzheimer's disease: a clinical observational study evaluating individual treatment response

    Riepe MW, Kohler J, Horn R · Current medical research and opinion · 2007

  56. 0.67

    The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study

    Gareri P, Castagna A, Cotroneo AM et al. · Journal of Alzheimer's disease : JAD · 2017

  57. 0.67

    Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type

    Bergman J, Brettholz I, Shneidman M et al. · Clinical neuropharmacology · 2003

  58. 0.66

    Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial

    Huang P, He XY, Xu M · Revista da Associacao Medica Brasileira (1992) · 2021

  59. 0.66

    Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies

    Mori E, Ikeda M, Nakagawa M et al. · Dementia and geriatric cognitive disorders · 2015

  60. 0.65

    Efficacy of donepezil combined with rehabilitation training in the treatment of Alzheimer's disease

    Yi Y, Deng X · Pakistan journal of medical sciences · 2025

  61. 0.64

    Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

    Pilotto A, Franceschi M, D'Onofrio G et al. · Neurology · 2009

  62. 0.64

    An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting

    Aguglia E, Onor ML, Saina M et al. · Current medical research and opinion · 2004

  63. 0.64

    Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial

    Barak Y, Bodner E, Zemishlani H et al. · Archives of gerontology and geriatrics · 2001

  64. 0.63

    Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease

    Zhang X, Yu R, Wang H et al. · Experimental and therapeutic medicine · 2020

  65. 0.62

    Effects of different administration protocols on the plasma concentration of donepezil hydrochloride in dementia patients with stage 5 chronic kidney disease

    Amano C, Ito T, Egawa M et al. · Nephron extra · 2013

  66. 0.61

    Safety and Pharmacokinetics of HTL0018318, a Novel M(1) Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects

    Bakker C, van der Aart J, Labots G et al. · Drugs in R&D · 2021

  67. 0.61

    Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials

    Tsoi KKF, Chan JYC, Leung NWY et al. · Journal of the American Medical Directors Association · 2016

  68. 0.61

    Effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) on cognitive impairment and serum levels of Abeta(1-42), tau, P-tau in patients with mild to moderate Alzheimer's disease

    Yang S, Fan D, Su S et al. · Zhongguo zhen jiu = Chinese acupuncture & moxibustion · 2024

  69. 0.61

    Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil

    Persson CM, Wallin AK, Levander S et al. · BMC neurology · 2009

  70. 0.61

    Caregiver-Reported Behavioral Changes After Donepezil Transdermal Patch Therapy in Alzheimer's Disease: An Exploratory Real-World Network Analysis

    Shimazu T, Hoshino E, Nakaseko M et al. · Neuropsychiatric disease and treatment · 2026

  71. 0.60

    Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease

    Cagnin A, Cester A, Costa B et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015

  72. 0.60

    Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

    Ikeda M, Mori E, Matsuo K et al. · Alzheimer's research & therapy · 2015

  73. 0.59

    Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

    Bartorelli L, Giraldi C, Saccardo M et al. · Current medical research and opinion · 2005

  74. 0.58

    Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease

    Ohta Y, Darwish M, Hishikawa N et al. · Geriatrics & gerontology international · 2017

  75. 0.56

    Depression and Alzheimer's disease: symptom or comorbidity?

    Moretti R, Torre P, Antonello RM et al. · American journal of Alzheimer's disease and other dementias · 2002

  76. 0.56

    Alzheimer's disease treated with combined therapy based on nourishing marrow and reinforcing Qi

    Chen S, Yao X, Liang Y et al. · Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2015

  77. 0.56

    Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease

    Okahara K, Ishida Y, Hayashi Y et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2010

  78. 0.52

    Caregiver burden, not patient cognitive impairment, predicts adherence to donepezil transdermal patch in Alzheimer's disease: A retrospective real-world study

    Yajima R, Ishiguro T, Michikawa M et al. · Journal of Alzheimer's disease reports · 2026

  79. 0.51

    Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies

    Manabe Y, Ino T, Yamanaka K et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2016

03case · medications75편

  1. 0.95

    Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index 이 논문

    Lee C, Lee K, Yu H et al. · Journal of clinical psychopharmacology · 2017

  2. 0.94

    Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report

    Li HC, Luo KX, Wang JS et al. · Medicine · 2020

  3. 0.94

    Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer's Disease

    Kuwahata S, Takenaka T, Motoya T et al. · Circulation reports · 2021

  4. 0.93

    Adverse effects associated with the use of donepezil in general practice in England

    Dunn NR, Pearce GL, Shakir SA · Journal of psychopharmacology (Oxford, England) · 2000

  5. 0.93

    Donepezil decreases heart rate in elderly patients with Alzheimer's disease

    Pu Z, Xu W, Lin Y et al. · International journal of clinical pharmacology and therapeutics · 2019

  6. 0.93

    Cardiac safety of donepezil in elderly patients with Alzheimer disease

    Isik AT, Yildiz GB, Bozoglu E et al. · Internal medicine (Tokyo, Japan) · 2012

  7. 0.93

    Syncope secondary to second-degree atrioventricular block with donepezil use

    Hundae A, Afzal A, Assar MD et al. · Proceedings (Baylor University. Medical Center) · 2014

  8. 0.92

    Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes

    Tanaka A, Koga S, Hiramatsu Y · Internal medicine (Tokyo, Japan) · 2009

  9. 0.92

    Urinary incontinence: an unrecognised adverse effect with donepezil

    Hashimoto M, Imamura T, Tanimukai S et al. · Lancet (London, England) · 2000

  10. 0.92

    Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023

    Yang Y, Wei S, Tian H et al. · Frontiers in pharmacology · 2024

  11. 0.92

    Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database

    Babai S, Auriche P, Le-Louet H · Therapie · 2010

  12. 0.92

    Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil

    Suleyman T, Tevfik P, Abdulkadir G et al. · Emergency medicine journal : EMJ · 2006

  13. 0.92

    Bilateral Lower Extremity Edema During Donepezil Treatment: A Case Report

    Kang K · Current drug safety · 2026

  14. 0.91

    Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System

    Morris R, Luboff H, Jose RP et al. · Journal of Alzheimer's disease : JAD · 2021

  15. 0.91

    Safety issues of Donepezil combined with Memantine in Alzheimer's disease population: real-world pharmacovigilance

    Zeng Y, Liu B, Zhou L et al. · Expert opinion on drug safety · 2026

  16. 0.91

    Safety Comparison of Acetylcholinesterase Inhibitors Using FAERS Spontaneous-Reporting Data: Drug-Specific Reporting Signals and Time-to-Onset Dynamics

    Du Y, Li J, Han F et al. · Current Alzheimer research · 2026

  17. 0.91

    Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database

    Kose E, Yamamoto T, Tate N et al. · Die Pharmazie · 2023

  18. 0.90

    Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial

    Campbell NL, Perkins AJ, Gao S et al. · Journal of the American Geriatrics Society · 2017

  19. 0.90

    Donepezil-Induced Severe Anorexia and T-Wave Inversion in Early-Onset Alzheimer's Disease: A Case Report

    Takahashi N, Kuroda T, Yoshioka T et al. · Clinical case reports · 2026

  20. 0.90

    Prescription cascades associated with acetylcholinesterase inhibitors use: a high-throughput sequence symmetry analysis

    Newby D, Bobba SS, Raventos B et al. · Age and ageing · 2026

  21. 0.90

    Deterioration in donepezil-induced PR prolongation after a coadministration of memantine in a patient with Alzheimer's disease

    Igeta H, Suzuki Y, Motegi T et al. · General hospital psychiatry · 2013

  22. 0.90

    Rhinorrhea as a Result of Alzheimer's Disease Treatment: A Case Report

    Bartlett D, Bear M · The Senior care pharmacist · 2019

  23. 0.90

    Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system

    Li S, Qian W, Zhang Z et al. · Frontiers in neurology · 2025

  24. 0.89

    Cholinesterase inhibitors and sexual disinhibition in dementia: a FAERS disproportionality study

    Sayion K · Naunyn-Schmiedeberg's archives of pharmacology · 2026

  25. 0.89

    Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase

    Kroger E, Mouls M, Wilchesky M et al. · The Annals of pharmacotherapy · 2015

  26. 0.89

    Frequency and Severity of Adverse Drug Reactions to Medications Prescribed for Alzheimer's Disease in a Brazilian City: Cross-Sectional Study

    Ferreira TR, Lopes LC, Bergamaschi CdC · Frontiers in pharmacology · 2020

  27. 0.89

    Fatal aspiration pneumonia during transition from donepezil to rivastigmine

    Taylor AM, Hoehns JD, Anderson DM et al. · The Annals of pharmacotherapy · 2002

  28. 0.89

    Donepezil-induced myoclonus in a patient with Alzheimer disease

    Bougea A, Gerakoulis S, Anagnostou E et al. · The Annals of pharmacotherapy · 2014

  29. 0.89

    Development of donepezil-induced hypokalemia following treatment of cognitive impairment

    Kim D, Yoon HE, Park HS et al. · Yeungnam University journal of medicine · 2021

  30. 0.88

    Cholinergic symptoms with low serum cholinesterase from therapeutic cholinesterase inhibitor toxicity

    Leikin JB, Braund V, DesLauris C · The American journal of emergency medicine · 2014

  31. 0.88

    Donepezil and Memantine-Induced Second-Degree Atrioventricular Block: A Case Report

    Mahadevappa M, Hussain S, Manohar S · Hospital pharmacy · 2025

  32. 0.88

    Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database

    Liu K, Yang X, Kong L · Frontiers in pharmacology · 2026

  33. 0.88

    Donepezil-Induced Complex Multimodal Hallucinations: Two Cases and a Review of the Literature

    Pozzi FE, Tremolizzo L, Ferrarese C et al. · Case reports in neurology · 2022

  34. 0.88

    Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study

    Masurkar PP, Chatterjee S, Sherer JT et al. · Drugs & aging · 2022

  35. 0.87

    Delirium associated with donepezil in a patient with Alzheimer's disease: a case report

    Mollazadeh-Moghaddam K, Jamali A, Adili-Aghdam F et al. · Iranian journal of psychiatry · 2013

  36. 0.87

    Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community

    Stahl SM, Markowitz JS, Gutterman EM et al. · The Journal of clinical psychiatry · 2003

  37. 0.87

    Increased libido associated with donepezil treatment: a case report

    Segrec N, Zaman R, Pregelj P · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2016

  38. 0.86

    Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting

    Pariente A, Sanctussy DJR, Miremont-Salame G et al. · CNS drugs · 2010

  39. 0.86

    Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account

    · Prescrire international · 2011

  40. 0.86

    Lesson of the month 1: Prolonged QT syndrome due to donepezil: a reversible cause of falls?

    Jackson EG, Stowe S · Clinical medicine (London, England) · 2019

  41. 0.86

    Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients

    Yiannopoulou KG, Anastasiou AI, Kyrozis A et al. · Case reports in nephrology and dialysis · 2019

  42. 0.85

    Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

    Isik AT, Bozoglu E, Yay A et al. · American journal of Alzheimer's disease and other dementias · 2012

  43. 0.85

    Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER)

    Otani N, Kanda K, Ngatu NR et al. · Medicina (Kaunas, Lithuania) · 2024

  44. 0.85

    Comparative cardiovascular safety of dementia medications: a cross-national study

    Fosbol EL, Peterson ED, Holm E et al. · Journal of the American Geriatrics Society · 2012

  45. 0.85

    Comparison of cholinesterase inhibitor safety in real-world practice

    Carney G, Bassett K, Wright JM et al. · Alzheimer's & dementia (New York, N. Y.) · 2019

  46. 0.84

    Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database

    Kobayashi S, Sugama N, Nagano H et al. · Drugs - real world outcomes · 2023

  47. 0.84

    Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study

    Zhang N, Gan L, Xiang G et al. · Frontiers in pharmacology · 2023

  48. 0.84

    Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients

    Isotalo HK, Lehtovaara JK, Ekblad LL et al. · The Annals of pharmacotherapy · 2026

  49. 0.83

    Upper gastrointestinal bleed associated with cholinesterase inhibitor use

    Kok KS, Loke Y, Southgate J · BMJ case reports · 2015

  50. 0.82

    Case report: Post-traumatic memories triggered by donepezil in a dose-dependent pattern

    Wolff ML · The American journal of geriatric pharmacotherapy · 2012

  51. 0.82

    Prolonged QT interval, syncope, and delirium with galantamine

    Fisher AA, Davis MW · The Annals of pharmacotherapy · 2008

  52. 0.81

    Pharmacogenetics of Donepezil and Memantine in Healthy Subjects

    Ovejero-Benito MC, Ochoa D, Enrique-Benedito T et al. · Journal of personalized medicine · 2022

  53. 0.80

    Donepezil overdose: a tenfold dosing error

    Shepherd G, Klein-Schwartz W, Edwards R · The Annals of pharmacotherapy · 1999

  54. 0.79

    Clinical practice with antidementia drugs in a geriatric clinic

    Rungsanpanya T, Muangpaisan W, Praditsuwan R · Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2012

  55. 0.79

    Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice

    Umegaki H, Itoh A, Suzuki Y et al. · International psychogeriatrics · 2008

  56. 0.77

    Association of cognitive enhancers and incident seizure risk in dementia: a population-based study

    Ha J, Son NH, Park YH et al. · BMC geriatrics · 2022

  57. 0.76

    Comparative Post-Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database

    Aksoyalp ZS, Nemutlu-Samur D · International journal of geriatric psychiatry · 2024

  58. 0.74

    In the Balance: A Case of Neuroleptic Malignant Syndrome When Donepezil Is Added to Maintenance Haloperidol Decanoate

    Mican LM, Schulenberg S · The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2014

  59. 0.72

    Withdrawal syndrome after donepezil cessation in a patient with dementia

    Bidzan L, Bidzan M · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012

  60. 0.72

    Poisoning Exposures in People with Dementia (2014‒2019): A Retrospective Study

    Wojt IR, Cairns R, Tan ECK · Journal of the American Medical Directors Association · 2021

  61. 0.70

    Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine

    Warwick TC, Moningi V, Jami P et al. · Nature clinical practice. Neurology · 2008

  62. 0.70

    Donepezil induces ventricular arrhythmias by delayed repolarisation

    Kho J, Ioannou A, Mandal AKJ et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2021

  63. 0.69

    Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease

    · Prescrire international · 2007

  64. 0.67

    Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report

    Mimura Y, Kurose S, Takata T et al. · BMC neurology · 2020

  65. 0.65

    Cardiovascular effects of drugs used to treat Alzheimer's disease

    Howes LG · Drug safety · 2014

  66. 0.62

    Cholinergic symptoms and QTc prolongation following donepezil overdose

    Pourmand A, Shay C, Redha W et al. · The American journal of emergency medicine · 2017

  67. 0.61

    Treatment persistence with acetylcholinesterase inhibitors in Alzheimer's disease: Real-world evidence from a retrospective cohort study

    Ho BL, Liu CF, Huang YB et al. · Journal of Alzheimer's disease : JAD · 2026

  68. 0.58

    Drug adverse events and drop-out risk: a clinical case

    Scoyni RM, Aiello L, Trani I et al. · Archives of gerontology and geriatrics · 2007

  69. 0.57

    Donepezil-induced bradycardia in a schizophrenic patient with comorbid neurocognitive disorder: a case report and review of the literature

    Odenigbo N, Nkemjika S, Atolagbe A et al. · Journal of medical case reports · 2024

  70. 0.57

    Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence

    Watanabe N, Yamamura K, Suzuki Y et al. · Patient preference and adherence · 2012

  71. 0.54

    Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

    Hartmann S, Mobius HJ · International clinical psychopharmacology · 2003

  72. 0.54

    Tolerability of memantine monotherapy versus adding memantine as combination therapy

    Isaac E, Ney D, Serruya M et al. · Journal of the National Medical Association · 2022

  73. 0.53

    Community Pharmacists' Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD

    Marvanova M, Henkel PJ · Pharmacy (Basel, Switzerland) · 2017

  74. 0.51

    Movement disorders associated with acetylcholinesterase inhibitors in Alzheimer's dementia: A systematic review

    Rissardo JP, Caprara ALF · Brain circulation · 2025

  75. 0.50

    Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)

    Rosenbloom MH, Finley R, Scheinman MM et al. · Alzheimer disease and associated disorders · 2010

04cholinesterase inhibitors · galantamine19편

  1. 0.85

    Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease

    Christensen DD · Postgraduate medicine · 2012

  2. 0.85

    The safety and tolerability of donepezil in patients with Alzheimer's disease

    Jackson S, Ham RJ, Wilkinson D · British journal of clinical pharmacology · 2004

  3. 0.81

    Donepezil in severe Alzheimer's disease

    Winblad B · American journal of Alzheimer's disease and other dementias · 2009

  4. 0.79

    Relative tolerability of Alzheimer's disease treatments

    Alva G, Cummings JL · Psychiatry (Edgmont (Pa. : Township)) · 2008

  5. 0.74

    Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors

    Shi X, Lin X, Hu R et al. · American journal of Alzheimer's disease and other dementias · 2016

  6. 0.65

    A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease

    Deardorff WJ, Grossberg GT · Drug design, development and therapy · 2016

  7. 0.64

    Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia

    Owen RT · Drugs of today (Barcelona, Spain : 1998) · 2016

  8. 0.61

    Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

    Mohammad D, Chan P, Bradley J et al. · Expert opinion on drug safety · 2017

  9. 0.59

    Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics

    Cacabelos R · Neuropsychiatric disease and treatment · 2007

  10. 0.58

    High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

    Cummings JL, Geldmacher D, Farlow M et al. · CNS neuroscience & therapeutics · 2013

  11. 0.57

    Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease

    Berk C, Sabbagh M · International journal of Alzheimer's disease · 2012

  12. 0.56

    Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

    Periclou AP, Ventura D, Sherman T et al. · The Annals of pharmacotherapy · 2004

  13. 0.54

    New Drugs IV

    · · 1994

  14. 0.54

    Clinical profile of donepezil in the treatment of Alzheimer's disease

    Doody RS · Gerontology · 1999

  15. 0.54

    Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

    Dantoine T, Auriacombe S, Sarazin M et al. · International journal of clinical practice · 2006

  16. 0.54

    Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease

    Imbimbo BP · CNS drugs · 2001

  17. 0.53

    An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease

    Calhoun A, King C, Khoury R et al. · Expert opinion on pharmacotherapy · 2018

  18. 0.53

    Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles

    Shigeta M, Homma A · CNS drug reviews · 2001

  19. 0.51

    Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology

    Nordberg A, Svensson AL · Drug safety · 1998

05delivery · oral16편

  1. 0.93

    Long-Term Safety, Tolerability, and Efficacy of a Transdermal Donepezil Patch in Patients with Severe Alzheimer's Disease

    Nakamura Y, Narita K, Kim R et al. · Journal of Alzheimer's disease : JAD · 2023

  2. 0.92

    Efficacy and Safety of a Transdermal Donepezil Patch in Patients with Mild to Moderate Alzheimer's Disease: Open-Label, Extension Study

    Nakamura Y, Omori T, Kim R et al. · Journal of Alzheimer's disease : JAD · 2023

  3. 0.84

    Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease

    Sadowsky CH, Dengiz A, Olin JT et al. · American journal of Alzheimer's disease and other dementias · 2009

  4. 0.80

    Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

    Tariot PN, Braeckman R, Oh C · Journal of Alzheimer's disease : JAD · 2022

  5. 0.79

    Switching from Oral Cholinesterase Inhibitors to a Transdermal Donepezil Patch Attenuated Gastrointestinal Symptoms and Allowed Treatment Continuation in Three Patients with Alzheimer's Disease in Clinical Settings

    Motoi Y, Sanjo N · Brain sciences · 2026

  6. 0.78

    Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer's Disease in South Korea: RECAP Study Results

    Lee KJ, Cho SJ, Kim BC et al. · Advances in therapy · 2017

  7. 0.76

    Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed-Dose Combination Versus Single-Component Tablets in Healthy Korean Males

    Choi M, Jin BH, Keum DH et al. · Clinical pharmacology in drug development · 2025

  8. 0.76

    New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient

    Suwata J, Kamata K, Nishijima T et al. · Nephron · 2002

  9. 0.75

    Pharmacokinetic Evaluation of GB-5001, a Long-Acting Injectable Formulation of Donepezil, in Healthy Korean Participants: Population Pharmacokinetics with Phase 1 Study

    Park YC, Seol E, Lee J et al. · Pharmaceutics · 2025

  10. 0.68

    Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan

    Lai TH, Wang WF, Yip BS et al. · Patient preference and adherence · 2016

  11. 0.68

    A study of once-a-week donepezil transdermal system's bioequivalence to oral donepezil in healthy volunteers: a plain language summary

    Braeckman R, Oh C · Neurodegenerative disease management · 2023

  12. 0.67

    Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study

    Kim KA, Lim JL, Kim C et al. · Clinical therapeutics · 2011

  13. 0.62

    A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers

    Boinpally R, Chen L, Zukin SR et al. · Clinical drug investigation · 2015

  14. 0.61

    Donepezil dosing strategies: pharmacokinetic considerations

    Gomolin IH, Smith C, Jeitner TM · Journal of the American Medical Directors Association · 2011

  15. 0.60

    Nose-to-brain delivery of donepezil within a small dose improves bioavailability and efficacy for Alzheimer's disease treatment

    Wang G, Duan X, Ouyang D et al. · Asian journal of pharmaceutical sciences · 2026

  16. 0.50

    Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan

    Ueda K, Katayama S, Arai T et al. · Dementia and geriatric cognitive disorders extra · 2019

06trials · systematic review15편

  1. 0.92

    Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis

    Nham T, Garcia MC, Tsang KLJ et al. · Journal of the American Geriatrics Society · 2024

  2. 0.89

    Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis

    Wang H, Zong Y, Han Y et al. · Expert opinion on drug safety · 2022

  3. 0.66

    Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review

    Chen Y, Lai M, Tao M · Medicine · 2024

  4. 0.66

    Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis

    Bittner N, Funk CSM, Schmidt A et al. · Drugs & aging · 2023

  5. 0.62

    Donepezil for mild cognitive impairment

    Birks J, Flicker L · The Cochrane database of systematic reviews · 2006

  6. 0.61

    Donepezil for dementia in people with Down syndrome

    Mohan M, Carpenter PK, Bennett C · The Cochrane database of systematic reviews · 2009

  7. 0.60

    Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis

    Lanctot KL, Herrmann N, Yau KK et al. · CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003

  8. 0.60

    The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis

    Kobayashi H, Ohnishi T, Nakagawa R et al. · International journal of geriatric psychiatry · 2016

  9. 0.60

    Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis

    Blanco-Silvente L, Castells X, Garre-Olmo J et al. · European journal of clinical pharmacology · 2019

  10. 0.59

    Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

    Tan CC, Yu JT, Wang HF et al. · Journal of Alzheimer's disease : JAD · 2014

  11. 0.56

    A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment

    Amanzio M, Benedetti F, Vase L · International psychogeriatrics · 2012

  12. 0.55

    Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis

    Chen Yd, Zhang J, Wang Y et al. · European neurology · 2016

  13. 0.55

    Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis

    Battle CE, Abdul-Rahim AH, Shenkin SD et al. · The Cochrane database of systematic reviews · 2021

  14. 0.53

    Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence

    Lockhart IA, Mitchell SA, Kelly S · Dementia and geriatric cognitive disorders · 2009

  15. 0.52

    Patnode CD, Perdue LA, Rossom RC et al. · · 2020

07induced · model4편

  1. 0.63

    Preventing Donepezil-Induced Adverse Effects Through N-acetylcysteine Co-Administration

    Park J, Oh JP, Ku K et al. · Journal of Alzheimer's disease : JAD · 2024

  2. 0.60

    Donepezil inhibits neuromuscular junctional acetylcholinesterase and enhances synaptic transmission and function in isolated skeletal muscle

    Redman RR, Mackenzie H, Dissanayake KN et al. · British journal of pharmacology · 2022

  3. 0.55

    No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model

    Baakman AC, Alvarez-Jimenez R, Loewen G et al. · Alzheimer's & dementia (New York, N. Y.) · 2019

  4. 0.54

    Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid-beta processing effects

    Voglein J, Willem M, Trambauer J et al. · Neurobiology of aging · 2019

08compounds · ache1편

  1. 0.51

    Lumacaftor and fexofenadine prevent donepezil-induced LQTS via PHE656-mediated hERG chaperoning

    Li Y, Li X, Ren J et al. · Biochemical pharmacology · 2026